pegpleranib
Trade name: Fovista
Nucleic acidexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00569140)
Timeline
Indications
Mechanism of action
PDGFA agonist
PDGFB inhibitor
Specifically supresses PDGF-B, thereby limiting the recruitment and maturation of pericytes, which in turn induces neovascular regression.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301576 ↗
Also known as
- e01aj
- e10030
- e10030
- fovista
- pegpleranib sodium
- x01e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02859441 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | National Eye Institute (NEI) |
| NCT02387957 | Phase 2 | Feb 1, 2015 | Iveric Bio |
| NCT02214628 | Phase 2 | Jul 1, 2014 | Iveric Bio |
| NCT01940887 | Phase 3 | May 1, 2014 | Iveric Bio |
| NCT02591914 | Phase 1 | Feb 1, 2014 | Iveric Bio, Retinal Consultants of Arizona |
| NCT01944839 | Phase 3 | Aug 1, 2013 | Iveric Bio |
| NCT01940900 | Phase 3 | Aug 1, 2013 | Iveric Bio |
| NCT01089517 | Phase 2 | Mar 1, 2010 | Iveric Bio |
| NCT00569140 | Phase 1 | Dec 1, 2007 | Iveric Bio |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Iveric Bio | For profit | 8 | 7 | 3 | 2007 |
| National Eye Institute (NEI) | Government | 1 | 1 | 1 | 2016 |
| Retinal Consultants of Arizona | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1